| News
Tessera Therapeutics Appoints Industry Leaders Elliott Sigal & Mary Rozenman to Board of Directors
From Business Wire
| News
Tessera Therapeutics Appoints Industry Leaders Elliott Sigal & Mary Rozenman to Board of Directors
From Business Wire
| News
From Business Wire
| News
Tessera Therapeutics scores $230M to ramp up 'gene writing' tech to cure disease
From FierceBiotech
| News
Programmable genetics gets more cash as Tessera Therapeutics gets a $230 million infusion
From Techcrunch
| News
Tessera Therapeutics Corrals More Than $230 Million for New Genetic Medicines
From WSJ VenturePro
| News
From Endpoints
| News
Biotech startup Tessera takes in $230m to go after ‘gene writing’
From Boston Globe
| News
| News
Writing a New Chapter of Genetic Medicine
From RARECast Podcast
| News
Podcast: When CRISPR won’t cut it—Writing new genes to treat deadly diseases
From Genetic Literacy Project
| News
Gene Writing: New Tech to Correct Disease
From Talking Biotech Podcast
| News
From Endpoints News
| News
Tessera highlighted by Business Insider as a biotech startup poised to take off
From Business Insider
| News
From gene editing to gene writing
From BioWorld
| News
Tessera: engineering mobile genetic elements for gene insertion
From BioCentury
| News
This Company Wants to Rewrite the Future of Genetic Disease
From WIRED
| News
From Endpoints News
| Press Release
By Tessera Therapeutics
| News
From Flagship Pioneering
| Essay
Barbara McClintock’s Contributions to Biology
By Jake Rubens